The Real-world Treatment Satisfaction by Gefapixiant in RCC

Recruiting now · Not applicable

Conditions studied: Chronic Cough

In brief

Chronic cough has a high global prevalence and it is refractory to such treatments by approximately 20% of patients. Gafapixant is a P2X3 receptor antagonist that has demonstrated the reduction of cough in patients with refractory chronic cough(RCC). Taste disturbance is the most frequent adverse event by gefapixant (approximately 60-70%). Although gefapixant is well-tolerated even if taste disturbance has occurred, the impact of taste disturbance on cough-specific QoL remains to be unclear. Therefore, the investigator would like to evaluate factors related to treatment satisfaction by gefapixant in RCC patients. the investigator hypothesize that taste disturbance will be associated with the improvement of cough specific QoL and treatment satisfaction in RCC patients.

Key facts

Study ID

NCT06542484

Run by

Nagoya City University

People needed

63

Starts

2024-12-04

Expected to finish

2026-06-30

Last updated by the study team

2025-01-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients with RCC and UCC (8 weeks or more).
• Cough is refractory to intensive specific treatments for causes of chronic cough.
• Never smokers and ex-smokers with having smoking history of ≤20 pack-years.

You may not qualify if…

• Patients with lung cancer, interstitial lung diseases, bronchiectasis, or respiratory infection such as tuberculosis and acute pneumonia.
• Current smoker, ex-smokers with having smoking history of >20 pack-years, or those who quit smoking within six months prior to receiving gefapixant.
• Those who are pregnant.

Where it is running

• Nagoya City University Hospital — Nagoya, Aichi-ken, Japan (enrolling)
• Nagoya City University — Nagoya, Aichi-ken, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.